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demographics, comorbidities, institution and operator’s
experience using propensity method. Long-term survival
of the matched groups was compared by Kaplan Meier
analysis.
Results: For eAAAs, perioperative mortality was signif-
icantly lower among EVAR recipients compared to OAR
recipients for both men and women (1.56% vs 3.86% for
men and 2.84% vs 5.36% for women, p  0.0001). One
difference, however, is that the EVAR survival benefit was
sustained in women but disappeared in men after 1.5 years.
Relatedly, the survival benefit of men over women after
elective EVAR disappeared after 1.5 years. For rAAAs,
30-daymortality was significantly lower amongmale EVAR
recipients compared OAR recipients (37.70% vs 47.62%,
p  0.0001) but this was not the case for women (46.99%
vs 47.81%, p0.05). Three-year survival was significantly
higher for men who received EVAR compared to OAR
(p  0.0053), but this treatment modality difference was
not seen among women. Moreover, survival was substan-
tially higher for men after emergent EVAR (p  0.0036).
Conclusions: Gender disparity is evident from long-
term outcomes after AAA repair. This is especially the case
for rAAA, where the long-term outcome for women was
significantly worse than for men and where the less invasive
treatment modality of EVAR did not appear to benefit
women as it did for men. These associations require further
study to isolate specific risk factors that would be potential
targets for improving AAA management.
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Objectives: To analyze outcomes of bilateral percuta-
neous (PC) vs femoral cutdown (FC) access for endovas-
cular repair (EVAR) of AAA.
Methods: We used NSQIP 2005-07. We selected pa-
tients, using ICD-9 & CPT codes, with intact (iAAA)
aneurysm, undergoing bifurcated EVAR. Cohorts were
defined by presence/absence of CPT for FC. We excluded
femoral-femoral bypass & brachial access patients.
Results: We isolated 5086 repairs. PC use increased
over time (36 - 46%). Females underwent FC more often
(61 vs 39%; p 0.05). Comorbidities were similar between
groups, except for ASA class, which was higher with PC
(3.14 vs 3.07; p  0.01). PC patients received general
anesthesia more often (82 vs 78%; p  0.01). Mean dura-tion of anesthesia (3.5 vs 3.7 hrs) and operative time (2.3 vs
2.5 hrs) were lower with PC (all p  0.01). 30 d mortality
(1.2% PC vs 0.9% FC) aggregate morbidity (9.5% PC vs
8.6% FC) and intraoperative blood transfusions (11% PC vs
10% FC; p 0.23) were similar between groups. Although
uncommon,MI (0.3 vs 0.1%; p 0.05), pneumonia (1.6 vs
1.0%; p  0.05) and DVT (1.1 vs 0.3%; p  0.01) were
higher with PC without a significant decrease in infections
(1.6 vs 2.4%; p 0.16) or length of stay (mean: 2.6 vs 3.0d;
p  0.47). Female sex, was independently predictive of
worse morbidity (OR: 1.7[1.3, 2.1]) and mortality (OR:
1.9[1.0, 3.6]).
Conclusions: Percutaneous access is being performed
increasingly with no benefit in rates of wound infection or
30-day mortality. Contrary to previous reports, PC is asso-
ciated with higher rates of MI, pneumonia, DVT as well as
greater use of general anesthesia, indicating that the poten-
tial benefit of decreased sedation is not being exploited.
Better selection criteria are needed tomaximize the benefits
of percutaneous access.
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Objectives: Endovascular interventions have largely
replaced surgical treatment of aortoiliac occlusive disease.
This review reports on current indications and outcomes of
surgical bypass of AIOD.
Methods: Retrospective review of all patients treated
for AIOD. Kaplan-Meier and logistic regression analyses of
all variables were applied.
Results: 2200 patients underwent interventions for
AIOD between 2000-08: only 205 (9.3%) had a surgical
bypass: 142 aortofemoral and 63 axillofemoral.Mean age was
64.4 10.8 (54%males) (Table 1). Mean FUwas 25.3mths.
Indications were claudication (25%) or critical limb ischemia
(75%, 15% acute ischemia). All but nine patients had bilateral
iliac occlusions (61) aortic occlusion to the renals (57) or both
(56). Prior endovascular interventions were present in 36%:
failed iliac angioplasty/stent in 29% and a failed recanalization
in 7%. The mean ABI increased from 0.32 0.20 to 0.85
0.22 post op. Patients with an ax-fem bypass had more co-
morbidities and a highermortality (HR 7.9, p 0.001). At
